For decades, pharma’s competitive race was largely about discovery: who could develop the next breakthrough molecule, complete trials, and bring it to market first.
That race hasn’t disappeared.
But another race is becoming just as important:
Who can make the right decision faster?
In a business where clinical, manufacturing, supply, market, and commercial signals change continuously, waiting days or weeks for insights can create a meaningful competitive disadvantage.
This is the idea behind Decision Velocity—how quickly an organization can move from detecting a signal to understanding it, deciding what to do, and putting that decision into action.
It is not simply about faster reporting.
It is about shortening the distance between data and impact.
What Is Decision Velocity?
Decision Velocity can be viewed through three connected measures:
- Time to Insight How quickly can teams turn raw data into something meaningful? A delayed insight creates blind spots. A timely insight gives teams an opportunity to respond before a problem becomes expensive—or before an opportunity disappears.
- Time to Decision Once the organization understands what is happening, how quickly can the right people make a decision? This depends on more than technology. Governance, trust, ownership, and cross-functional collaboration all influence how quickly decisions move.
- Time to Action A decision has limited value if execution takes weeks. The final measure is how quickly the organization can translate a decision into a real-world change—whether that means adjusting a clinical program, changing production plans, reallocating commercial resources, or responding to market conditions. When all three improve, the organization becomes more responsive. The Hidden Cost of Slow Decisions In pharma, delays rarely remain isolated. A slow decision in one function can create consequences elsewhere. Manufacturing A delayed quality signal can lead to additional production disruption. Slow interpretation of supply and demand signals can contribute to shortages, excess inventory, or inefficient capacity utilization. Predictive monitoring can help manufacturing teams identify potential problems earlier and respond before they become costly disruptions. Clinical Development Clinical programs generate enormous volumes of data. If teams take too long to identify recruitment issues, safety patterns, or operational bottlenecks, the consequences can include longer timelines and higher development costs. The value of analytics is therefore not just in finding patterns. It is in finding them early enough to matter. Commercial Operations Commercial organizations face a similar challenge. Market conditions can shift quickly. Physician behavior, patient demand, access conditions, competitor activity, and treatment patterns can all change. If teams are still analyzing last month's performance while the market has already moved, the insight may arrive too late. This is particularly relevant when using HCP targeting or other segmentation approaches. Historical data remains useful, but faster feedback allows teams to continuously refine where and how commercial resources are deployed. The ROI of Moving Faster Decision velocity should not be treated as an abstract technology metric. It can translate into measurable business outcomes. A faster decision cycle can contribute to: Reduced reporting and analysis time Earlier identification of operational problems Better resource allocation Improved forecasting Faster response to market changes Greater analyst productivity More efficient commercial execution Consider a traditional reporting process that requires several days to collect, clean, analyze, review, and distribute information. If automation, governed data pipelines, and real-time analytics reduce that cycle to a few hours, the organization hasn't simply produced a dashboard faster. It has created additional time to interpret, decide, and act. That distinction is important. The ROI comes from what the organization does with the time it gains. AI Can Accelerate the Decision Cycle AI can significantly increase Decision Velocity when it is built on reliable data and connected to the right workflows. Instead of waiting for a periodic report, organizations can use AI to continuously monitor important signals and surface anomalies as they emerge. Three capabilities are particularly valuable: Continuous monitoring AI can track large numbers of variables across clinical, operational, supply, and commercial environments without requiring analysts to manually inspect every data point. Predictive alerts Models can identify patterns that may indicate future problems, allowing teams to investigate before an issue becomes material. Automated root-cause analysis When something changes unexpectedly, AI can help narrow down the variables most likely responsible, reducing the time analysts spend searching through disconnected datasets. The shift is significant: From periodic reporting → continuous intelligence But speed should never come at the expense of accuracy, governance, or human judgment. Faster wrong decisions are still wrong decisions. From Five-Day Cycles to Same-Day Decisions The traditional decision process often looks like this: Manual data collection → batch reporting → departmental review → decision → manual follow-up A modern model can look very different: Automated ingestion → continuously refreshed intelligence → collaborative review → decision → workflow-triggered action The objective isn't necessarily to make every decision instantaneous. Some decisions require careful review. The goal is to remove unnecessary waiting from the process so that the time spent on analysis and deliberation is focused where it actually adds value. That is what makes speed sustainable. Data Quality Is the Foundation of Speed There is a common misconception that Decision Velocity is primarily an AI problem. It isn't. AI can accelerate analysis, but it cannot fix fragmented, poorly governed, or unreliable data on its own. Before organizations can expect faster decisions, they need: Reliable data pipelines Consistent definitions Strong data governance Clear ownership Automated validation Accessible analytical models Appropriate security controls This is especially important as organizations expand pharmaceutical commercial analytics across brands, markets, and functions. If every team uses different definitions, data sources, or reporting logic, faster analytics can actually increase confusion. The foundation must be trusted before it can be fast. Culture Is the Final Accelerator Technology creates the possibility of faster decisions. Culture determines whether the organization actually makes them. Leaders need to encourage: Data as a shared asset Teams should be able to access trusted information without rebuilding the same analysis repeatedly. Speed with accountability Employees should be encouraged to act on reliable signals while maintaining appropriate governance. Cross-functional decision-making Clinical, manufacturing, supply, market access, and commercial teams should not operate as completely separate analytical environments. Continuous learning Every decision should generate feedback that improves the next decision. The objective is not simply to create faster reports. It is to create an organization that can sense, learn, decide, and respond faster. Measuring Decision Velocity If pharma leaders want to make decision speed a strategic capability, they should measure it. Useful metrics include: Average time from data availability to insight Average time from insight to decision Average time from decision to execution Percentage of decisions supported by automated intelligence Time spent on manual data preparation Frequency of delayed decisions caused by data availability Adoption of analytical recommendations Business impact following faster decisions These metrics shift the conversation from: "How many dashboards did we build?" to: "How much faster are we making better decisions?" That is a much more meaningful measure of analytics maturity. The Competitive Edge Is No Longer Just Data Most large pharma organizations already have enormous amounts of data. The advantage increasingly comes from what happens between having the data and acting on it. Two companies may have access to similar information. One spends five days preparing and reviewing it. The other identifies the signal within hours, validates it, brings the right stakeholders together, and acts. Over time, that difference compounds. Faster responses can mean earlier operational corrections, better resource allocation, more responsive commercial strategies, and fewer missed opportunities. That is the real ROI of Decision Velocity. The next generation of pharma leaders won't simply ask how much data their organization has. They will ask: How quickly can we turn trusted data into confident action? Because in an industry where every delay can affect cost, timelines, competitiveness, and ultimately patient access, speed is no longer just an operational advantage. It is becoming a strategic one.
